SCHEMBL14928720

SCHEMBL14928720

CCCC(OC(=O)c1ccc([N+](=O)[O-])cc1)C(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 2/20 0.48
ADRB1 P08588 2/20 0.48
ADRB3 P13945 2/20 0.48
SLC6A2 P23975 1/20 0.48
SLC6A4 P31645 1/20 0.48
SLC6A3 Q01959 1/20 0.48
L3MBTL1 Q9Y468 3/20 0.47
ATM Q13315 1/20 0.47
POLB P06746 2/20 0.46
MAPK1 P28482 1/20 0.45
KMT2A Q03164 5/20 0.45
MEN1 O00255 4/20 0.45
ALDH1A1 P00352 3/20 0.45
MAPT P10636 2/20 0.45
CES1 P23141 1/20 0.44
BCL9 O00512 1/20 0.43
CTNNB1 P35222 1/20 0.43
ALOX12 P18054 1/20 0.43
RAB9A P51151 1/20 0.43
HDAC3 O15379 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14928993 0.92 HDAC3 (0.47) ADRB2ADRB1ADRB3SLC6A2SLC6A4
SCHEMBL14928557 0.89 L3MBTL1 (0.48) ADRB2ADRB1ADRB3SLC6A2SLC6A4
SCHEMBL15081479 0.89 ADRB2 (0.46) ADRB2ADRB1ADRB3SLC6A2SLC6A4
SCHEMBL14928965 0.89 ADRB2 (0.50) ADRB2ADRB1ADRB3L3MBTL1ATM
SCHEMBL6233407 0.87 CA12 (0.47) SLC6A2SLC6A4SLC6A3MAPK1ALDH1A1
SCHEMBL14928772 0.84 MAPK1 (0.50) ADRB2ADRB1ADRB3L3MBTL1ATM
SCHEMBL26344781 0.83 ADRB2 (0.48) ADRB2ADRB1ADRB3L3MBTL1ATM
SCHEMBL8446208 0.82 PRKCA (0.52) ADRB2ADRB1ADRB3SLC6A2SLC6A4
SCHEMBL14929732 0.82 L3MBTL1 (0.51) ADRB2ADRB1ADRB3L3MBTL1ATM
SCHEMBL3370602 0.82 HDAC3 (0.45) ADRB2ADRB1ADRB3SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9051310-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2015-06-09 US disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-20140309225-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2014-10-16 US disclosed
US-8809371-B2 2014-08-19 US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, CD38, BTK ADRB2 1774/4885ADRB1 940/4885ADRB3 926/4885
US-20140309225-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, BTK, NOX4 ADRB2 1972/4885ADRB1 1007/4885ADRB3 1393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.